In MYCN-amplified SKNBE2 neuroblastoma cells, SF2523 reduced MYCN mRNA and MYCN/Cyclin D1 protein while inhibiting AKT Ser473 phosphorylation. JQ1 reduced MYCN-related readouts without reducing pAKT, whereas CAL101 did not displace BRD4 from the MYCN promoter. RNA/protein assays and promoter-occupancy assays used different SF2523 concentrations and timings. [1]
Cell-free BRD4 binding and histone-peptide displacement
Biochemical assay · BRD4 full-length protein and isolated BRD4 BD1/BD2; comparator bromodomains and PI3Kα enzyme assay [1]
SF2523 bound BRD4 and displaced acetylated histone peptide. BD1 affinity exceeded BD2 affinity, and binding also extended to BRD2/BRD3. The enzyme-assay table independently identifies PI3Kα inhibition; no PI3K potency number is adopted because a sentence in the Results ambiguously assigns the 16 nM value.
Literature-Reported Treatment Conditions
- Method
- Cell-free binding and displacement assays; separate PI3K ADAPTA enzyme assay.
- Reported limits
- Main text does not provide all commercial-assay incubation and solvent conditions. Kd and IC50 are assay endpoints, not cell-treatment concentrations.
Methods and source locations
Compound reported in the paper: SF2523; Compound label in the paper: SF2523
Applies to the research compound SF2523, without supplier-lot equivalence or clinical efficacy claims.
Figures 1D and 2A–B; Results: BDs Are Targets of TP-Scaffold Inhibitors; Methods: Tissue Culture, Cell Lines, and Reagents; Binding and Displacement Assays and Kinase Screening
SF2523 binding to full-length BRD4: BROMOscan binding assay — Figure 1D; Results: BDs Are Targets of TP-Scaffold Inhibitors; Methods: Binding and Displacement Assays and Kinase Screening
SF2523 binding to BRD4 BD1: BROMOscan binding assay — Figure 1D
SF2523 binding to BRD4 BD2: BROMOscan binding assay — Figure 1D
Displacement of tetra-acetylated histone H4 peptide from BRD4 BD1: AlphaScreen displacement assay using His-tagged bromodomains and H4K5ac/8ac/12ac/16ac-Biotin — Figure 2A–B; Methods: Binding and Displacement Assays and Kinase Screening
Displacement of tetra-acetylated histone H4 peptide from BRD4 BD2: AlphaScreen histone-peptide displacement assay — Figure 2A–B
Dual-pathway responses in MYCN-amplified neuroblastoma cells
Cell-based study · Human SKNBE2 neuroblastoma cells; IGF-stimulated signaling and MYCN-promoter ChIP assays [1]
SF2523 reduced MYCN transcript and MYCN/Cyclin D1 protein and inhibited AKT Ser473 phosphorylation. In the linked promoter-occupancy experiment, SF2523 displaced BRD4 at both tested MYCN promoter regions. JQ1 reduced MYCN-related readouts without inhibiting pAKT; CAL101 did not displace BRD4. These are pathway-response and promoter-occupancy data, not direct MYCN binding or a cell-viability IC50.
Literature-Reported Treatment Conditions
- Treatment concentration
- 5 μM SF2523 for RT-PCR and Western blotting; 2 μM SF2523 for ChIP.
- Exposure duration
- 24 h for RT-PCR and ChIP; 30 min for Western blotting.
- Method
- For RNA/protein assays, 4 h serum starvation followed by 50 ng/mL IGF stimulation and inhibitor treatment. ChIP used its separately reported conditions.
- Vehicle
- DMSO control for Figure 1A; no-inhibitor, anti-BRD4 and rabbit-IgG controls in ChIP.
- Co-treatment
- SF2523 alone. Separate comparator arms: JQ1, SF1126, BKM120, BEZ235 and CAL101; not a combined-drug treatment.
- Reported limits
- Figure 1A does not specify replicate count in its caption. Figure 1C specifies triplicate experiments. ChIP concentration differs from RNA/protein assays and is retained separately.
Methods and source locations
Compound reported in the paper: SF2523; Compound label in the paper: SF2523
Applies to the research compound SF2523, without supplier-lot equivalence or clinical efficacy claims.
Figure 1A–C; Results: Morpholinothienopyrane Is a Dual Inhibitor of PI3K and BRD4; Methods: Tissue Culture, Cell Lines, and Reagents; Western Blotting; RNA Extraction and RT-PCR; ChIP
MYCN mRNA relative to DMSO control: RT-PCR normalized to GAPDH — Figure 1A; Results: Morpholinothienopyrane Is a Dual Inhibitor of PI3K and BRD4; Methods: RNA Extraction and RT-PCR
MYCN, Cyclin D1 and AKT Ser473 phosphorylation: Western blotting with total AKT and β-actin controls — Figure 1B; Methods: Western Blotting
BRD4 occupancy at MYCN promoter R-1 and R-2: BRD4 ChIP-qPCR; input normalization, rabbit IgG and a MYCN negative-control region; ±SEM from triplicate experiments — Figure 1C; Methods: ChIP